Prasugrel Mylan is taken together with aspirin to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries) in patients with acute coronary syndrome who are undergoing percutaneous coronary intervention. Acute coronary syndrome is a group of conditions in which blood supply in the vessels supplying the heart is interrupted so heart tissue cannot work properly or dies. It includes unstable angina (a severe type of chest pain) and heart attack. Percutaneous coronary intervention is a procedure used to unblock the blood vessels supplying the heart. Prasugrel Mylan contains the active substance prasugrel and is a ‘generic medicine’. This means that Prasugrel Mylan contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called Efient.
Therapeutic Indication
### Therapeutic indication Prasugrel Viatris, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndrome (i.e. unstable angina, non-ST segment elevation myocardial infarction \[UA/NSTEMI\] or ST segment elevation myocardial infarction \[STEMI\]) undergoing primary or delayed percutaneous coronary intervention (PCI).
Therapeutic Area (MeSH)
ATC Code
B01AC22
ATC Item
prasugrel
Pharmacotherapeutic Group
Antithrombotic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| prasugrel besilate | N/A | prasugrel besilate |
EMA Name
Prasugrel Viatris (previously Prasugrel Mylan)
Medicine Name
Prasugrel Viatris (previously Prasugrel Mylan)
Aliases
N/A